More than two-thirds (68%) of the respondents to the survey expressed confidence that the COVID-19 is "behind us." An overwhelming majority (80%), though, indicated that annual COVID-19 vaccination will be needed for the foreseeable future.
Most every measure of the COVID-19 pandemic is trending downward, according to the Centers for Disease Control and Prevention (CDC). The CDC tracker this morning shows 1,052 deaths on weekly basis and an average of 1,511 daily hospitalization admissions.
Although the 2023 Annual Managed Healthcare Executive Pharmacy Survey was conducted Feb. 14-28, just over two-thirds (68%) of the approximately 300 respondents indicated then they were confident or very confident that the COVID-19 “was behind us.” Just 9% indicated that they were not confident that was not so.
Whether the methods used to count COVID-19 deaths are undercounting or overcounting the deaths from the disease has become an active controversy. In her column in the Washington Post, Leana Wen, M.D., M.Sc., a professor George Washington’s Milken Institute School of Public Health has argued that deaths being overcounted. Others have argued that the problem is undercounting.
Respondents to the Pharmacy Survey were solidly in the overcounting camp, with two-thirds (67%) indicated that they believed that deaths from COVID-19 were being overcounted. Nonetheless, a large majority (80%) said they believe annual COVID-19 vaccines will be needed for the foreseeable future.
The respondents were spread fairly evenly across the various sectors of the U.S. healthcare industry, with 20% self-identifying as working for hospitals, 22% for physician practices, 19% for pharmacy benefit managers, 16% for payer organizations, 13% for drug and device manufacturers and the rest in a variety of sectors.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More